Bioprojet announces the signing of a strategic agreement with CR Sanjiu for the commercialization of WAKIX® in China
![[BREAKING NEWS] An international recognition for a visionary scientist](https://www.bioprojet.com/app/uploads/2025/09/an-international-recognition-for-a-visionary-scientist-bioprojet.jpg.webp)
Paris, November 7th 2025 — Bioprojet is pleased to announce the conclusion of a major partnership with CR Sanjiu Medical & Pharmaceutical Co., Ltd., a leading player in the Chinese pharmaceutical industry. This agreement grants CR Sanjiu exclusive of WAKIX® (pitolisant) throughout mainland China.
More than an agreement : an international collaboration
This collaboration marks an important milestone in Bioprojet’s international strategy and demonstrates our commitment to making innovative solutions accessible to patients worldwide. By partnering with CR Sanjiu, Bioprojet leverages a trusted partner with proven expertise and an extensive distribution network to accelerate access to treatments tailored to the needs of Chinese patients.
About Bioprojet
Bioprojet is a French pharmaceutical research and development company dedicated to therapeutic innovation and improving patients’ quality of life worldwide.
About CR Sanjiu
CR Sanjiu, the healthcare branch of China Resources Group and a leading pharma company in China, is committed to developing innovative solutions to improve public health and enhance patients’ quality of life.